Prognostic value of cancer stem cell marker CD133 expression in esophageal carcinoma: A meta-analysis - PubMed (original) (raw)

Prognostic value of cancer stem cell marker CD133 expression in esophageal carcinoma: A meta-analysis

Yun-Peng Sui et al. Mol Clin Oncol. 2016 Jan.

Abstract

CD133 has been identified as a putative neoplastic stem cell marker in esophageal carcinoma. However, the prognostic value of CD133 overexpression in patients with esophageal carcinoma remains controversial. A meta-analysis of previous studies was performed, in order to assess the association of CD133 overexpression with the clinicopathological characteristics of esophageal carcinoma patients. A total of 7 studies, including 538 patients, were subjected to the final analysis. Our results indicated that a positive CD133 expression was significantly associated with lymph node metastasis [odds ratio (OR)=3.09, 95% confidence interval (CI): 1.93-4.95; P<0.00001], clinical stage (OR=4.26, 95% CI: 1.55-11.73; P=0.005) and histopathological grade (OR=2.40, 95% CI: 1.16-4.94; P=0.02). There was no statistically significant association of CD133 with depth of invasion (OR=1.89, 95% CI: 0.42-8.43; P=0.41). Based on the results of this study, we concluded that CD133 is an efficient prognostic factor in esophageal carcinoma. Higher CD133 expression is significantly associated with lymph node metastasis, clinical stage and histopathological grade.

Keywords: CD133; cancer stem cells; clinicopathological characteristics; esophageal carcinoma; meta-analysis; prognosis.

PubMed Disclaimer

Figures

Figure 1.

Figure 1.

Flow chart of the study selection process.

Figure 2.

Figure 2.

Forest plot of ORs for the association of CD133 expression with lymph node metastasis. OR, odds ratio; CI, confidence interval.

Figure 3.

Figure 3.

Forest plot of ORs for the association of CD133 expression with clinical stage. OR, odds ratio; CI, confidence interval.

Figure 4.

Figure 4.

Forest plot of ORs for the association of CD133 expression with histopathological grade. OR, odds ratio; CI, confidence interval.

Figure 5.

Figure 5.

Forest plot of ORs for the association of CD133 expression with depth of invasion. OR, odds ratio; CI, confidence interval.

Figure 6.

Figure 6.

Funnel plot analysis of publication bias for clinicopathological parameters. (A) Lymph node metastasis, (B) clinical stage, (C) histopathological grade and (D) depth of invasion. SE, standard error; OR, odds ratio.

References

    1. Shi HY, Zhu SC, Shen WB, Liu ML. Pathological characteristics of esophageal cancer. Oncol Lett. 2014;8:533–538. - PMC - PubMed
    1. Tomochika S, Iizuka N, Watanabe Y, Tsutsui M, Takeda S, Yoshino S, Ichihara K, Oka M. Increased serum cell-free DNA levels in relation to inflammation are predictive of distant metastasis of esophageal squamous cell carcinoma. Exp Ther Med. 2010;1:89–92. - PMC - PubMed
    1. Tan Y, Chen B, Xu W, Zhao W, Wu J. Clinicopathological significance of CD133 in lung cancer: A meta-analysis. Mol Clin Oncol. 2014;2:111–115. - PMC - PubMed
    1. He A, Qi W, Huang Y, Feng T, Chen J, Sun Y, Shen Z, Yao Y. CD133 expression predicts lung metastasis and poor prognosis in osteosarcoma patients: A clinical and experimental study. Exp Ther Med. 2012;4:435–441. - PMC - PubMed
    1. Bodzin AS, Wei Z, Hurtt R, Gu T, Doria C. Gefitinib resistance in HCC Mahlavu cells: Upregulation of CD133 expression, activation of IGF-1R signaling pathway, and enhancement of IGF-1R nuclear translocation. J Cell Physiol. 2012;227:2947–2952. doi: 10.1002/jcp.23041. - DOI - PubMed

LinkOut - more resources